NVIDIA and Eli Lilly announced a $1 billion partnership to create an AI‑powered drug discovery laboratory in the San Francisco Bay Area. The collaboration combines NVIDIA’s computing platforms and large‑scale AI capabilities with Lilly’s therapeutic expertise to accelerate target identification, molecular design, and preclinical candidate selection. Lilly and NVIDIA said the lab will host shared compute, models and teams to compress discovery timelines. The deal signals escalating tech‑pharma convergence and larger corporate commitments to deploy generative AI across the R&D lifecycle.